



## Evaluation of the Crimean-Congo Hemorrhagic Fever Cases Followed and Treated in Our Clinic between 2009-2013

İlhami Çelik<sup>1\*</sup>, Zehra Beştepe Dursun<sup>1</sup>, Filiz Kürklü Bozkır<sup>1</sup>, Fatma Bahadır<sup>1</sup>  
and Sibel Gürbüz<sup>1</sup>

<sup>1</sup>Department of Infectious Diseases, Kayseri Training and Research Hospital, Turkey.

### Authors' contributions

This work was carried out in collaboration between all authors. Authors IC and ZBD designed the study, wrote the protocol and wrote the first draft of the manuscript. Authors IC and ZBD managed the literature searches. Authors IC, ZBD, FKB, FB and SG followed and treated the patients. All authors read and approved the final manuscript.

### Article Information

DOI: 10.9734/BJMMR/2016/25724

#### Editor(s):

- (1) Vijayalakshmi i. Balekundri, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bengaluru, India.  
(2) Salomone Di Saverio, Emergency Surgery Unit, Department of General and Transplant Surgery, S. Orsola Malpighi University Hospital, Bologna, Italy.

#### Reviewers:

- (1) Shahzad Shaukat, National Institute of Health, Pakistan.  
(2) David Bukbuk, University of Maiduguri, Nigeria.  
(3) Triveni Krishnan, National Institute of Cholera and Enteric Diseases, Kolkata, India.  
Complete Peer review History: <http://sciencedomain.org/review-history/14344>

Original Research Article

Received 17<sup>th</sup> March 2016  
Accepted 18<sup>th</sup> April 2016  
Published 26<sup>th</sup> April 2016

### ABSTRACT

**Objectives:** The Crimean-Congo hemorrhagic fever virus (CCHFV) belongs to the family Bunyaviridae, genus Nairovirus, and causes severe disease in man; the reported case-fatality rate is 3%–30%. The aim of this study was to determine the epidemiological and clinical characteristics of the CCHF cases in our clinic between 2009-2013.

**Materials and Methods:** Thirty-three patients with the diagnosis of CCHF were followed up in Kayseri Training and Research Hospital between January 2009 and September 2013. Demographic, geographic, climatic, and clinical and laboratory characteristics of all patients were investigated. All of the cases were confirmed by CCHF immunoglobulin M (IgM) and/or PCR RNA positivity.

**Results:** According to our reports 33 CCHF cases were followed in our clinic. Of the CCHF cases,

\*Corresponding author: E-mail: [ilhamicelik@yahoo.com](mailto:ilhamicelik@yahoo.com);

63.6% were male. Thirty patients (90.9%) were from rural regions. Seventeen patients (51, 5%) were farmers. The median age was 46.7 years (range 18-71 years). On admission, 97% of patients experienced high fever, 100% had weakness, 93.9% had headache. The disease was more usual in May, June, July. Of the CCHF cases, 69.7% had a history of tick bite. On admission, all of the patients had thrombocytopenia, 87.9% had leucopenia, 27.3% had anemia, and 87.9% had elevated AST and ALT. Oral ribavirin treatment was used in 33.3% of the CCHF cases. The case-fatality rate was 12.1% (4/33 patients).

**Conclusions:** CCHF remains a seasonal problem in the Mid-Eastern Anatolia region of Turkey. The mortality rate in our patients was higher than reported in other studies in our country (12% vs 5%). CCHF should be accompanied with supportive care, especially including early platelet replacement.

*Keywords: Crimean-Congo hemorrhagic fever; case-fatality rate; tick-bite.*

## 1. INTRODUCTION

Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne viral zoonosis with the potential of human-to-human transmission with case fatality rates from 3% to 50% [1]. It is an endemic disease in Turkey and large outbreaks have been observed during spring and summer months since 2002 [2]. In Turkey, 5% case fatality rate (CFR) had been reported by the Ministry of Health of Turkey [3]. The primary transmission route of the virus to humans is known to be tick bite. Moreover, contact with patients at the viremic phase of the disease or exposure to tissue or blood of an infected animal can lead to the disease [4].

In the present study, demographic, geographic, climatic, clinical and laboratory features of the CCHF cases in our clinic followed up 5 years were analyzed and risk factors were measured.

## 2. METHODS

The patients with acute febrile syndrome characterized by fever, malaise, bleeding, leucopenia, and thrombocytopenia in spring and summer of 2009 and 2013 were admitted. Patients with a definite diagnosis of CCHF via clinical manifestations and the positive results of viral RNA by reverse transcriptase - polymerase chain reaction (RT-PCR) and/or specific IgM antibody were enrolled to the study. Blood samples were sent to the Public Health Institute of Turkey, National Arbovirus and Viral Zoonosis Reference and Research Laboratory Ankara, Turkey. The real time RT-PCR test was performed for serum samples with a RealStar® CCHFV RT-PCR Kit 1.0 (Altona Diagnostics, Hamburg, Germany). Demographic data of the data of patients, as well as clinical and the laboratory results, were recorded and transferred to the SPSS 20.0 (Statistical Package for the

Social Sciences 20.0) statistical package program.

## 3. RESULTS


The epidemiological characteristics of patients are shown in Table 1. Specific antibodies against CCHF virus were found in all patients' sera. The number of confirmed cases, according to the year include 2009 (4), 2010 (13), 2011 (8), 2012 (2) and 2013 (6). All patients admitted on in the spring and summer months when air temperatures rise above 20°C. The disease was most common in the months May, June and July. The greatest number of patients (30.3%) was accepted in July (Fig. 1).

Baseline clinical characteristics and laboratory are presented Table 2, Table 3 and Table 4.

According to the case report forms, oral ribavirin treatment was employed in 33.3% of the CCHF cases (Table 3). Hospital admission period after beginning symptoms was 3.2±1 days. The case-fatality rate was 12.1% (4/33 patients).

**Table 1. The epidemiological characteristics of patients with a diagnosis of CCHF**

Age (years, min-max)	46.7	18-71
	n	%
<b>Gender</b>		
Male	21	63.6
Female	12	36.4
Inhabiting in the rural region	30	90.9
<b>Occupation</b>		
Farmer	17	51.5
Housewife	7	21.2
Working in animal agriculture or as a shepherd	7	21.2
Student	1	3
Unemployed	1	3



**Fig. 1. Seasonal distribution of our CCHF cases; all the cases were followed in April to August; no cases were attended in other months**

**Table 2. Potential risk factors for transmission and clinical of CCHF cases**

Possible risk factors for transmission	n	%
Tick bite	23	69.7
Tick contact	19	57.6
Close contact with animals	32	97
Contact with the body fluid of a CCHF case	1	3
Living in the rural area	31	93.9
Activities in the nature	33	100
<b>Symptoms</b>		
Fatigue	33	100
Fever	32	97
Headache	31	93.9
Myalgia	32	97
Nausea	25	75.8
Vomiting	17	51.5
Abdominal pain	11	33.3
Diarrhea	10	30.3
Hemorrhage	7	21.2
<b>Signs</b>		
Body temperature >38°C	28	84.8
Hypotension	16	48.5
Tachycardia	15	45.5
Epistaxis	2	6.1
Gingival hemorrhage	3	9.1
Hematuria	6	18.2
Vaginal bleeding	1	3
Gastrointestinal system hemorrhage	2	6.1
Maculopapular rash	2	6.1

**Table 3. Laboratory findings, treatment and outcome in patients with a diagnosis of CCHF**

Laboratory findings	n	%
Anemia	9	27.3
Leukopenia	29	87.9
Thrombocytopenia	33	100
Elevated AST and ALT	29	87.9
Elevated CK	24	72.7
Elevated LDH	22	66.7
Abnormality at chest x-ray	5	15.2
<b>Treatment</b>		
Ribavirin	11	33.3
Supportive	24	72.7
<b>Outcome</b>		
Cured	29	87.9
Died	4	12.1
Duration of hospitalization (days ± SD)	7.81±2.9	

#### 4. DISCUSSION

CCHF was found to be endemic in the middle, northern, and eastern Turkey between the months of March and October [5,6]. Our cases were living in the similar area (Kayseri, Yozgat, Adana, Nevşehir, Sivas, Niğde) in the months May, June and July.

The virus can be transmitted to humans by tick bites or by contact with blood or tissue of CCHF patients or infected livestock [7]. Of the CCHF

cases 69.7% of our cases had a history of tick-biting or tick contact, 97% patients had a history of close contact with animals. The occupations at risk for CCHF have primarily been those that are engaged in animal husbandry and farming, which involve the risk of contact with ticks [8]. In our series, cases were mostly farmers (17 cases, 51.5%). The incidence rate of the disease among healthcare workers is very low in Turkey. In this study followed by 33 cases which there were no health workers.

**Table 4. The baseline laboratory of the patients with CCHF**

Laboratory findings	Median±SD
Leukocyte ( $10^3/\mu\text{L}$ )	2.6±1.7
Platelet ( $10^3/\mu\text{L}$ )	71.4±37.2
Hemoglobin (g/dL)	13.8±1.8
Aspartate-Aminotransferase (IU/mL)	287±322
Alanine-Aminotransferase (IU/mL)	142±135
Creatine phosphokinase (IU/mL)	710±749
Lactate dehydrogenase (IU/mL)	520±354
Prothrombin time (sec)	13.7±2.4
Activated partial thromboplastin time (sec)	37.6±17.1
International normalized ratio	1.1±0.2

In the present study, male patients were dominant (63.6%). In our region, men work in all types of farming household tasks and tend livestock in rural areas.

Evaluation of clinical findings showed that the most common symptoms were tiredness, fever, myalgia and headache [8-11]. In this study, the most common reported complaints were fatigue, myalgia, headache and fever. The hemorrhages observed in patients may be in the form of epistaxis, hematemesis, melena, hematuria, gingival hemorrhage, vaginal bleeding, petechial or ecchymosis as well as occult hemorrhage without any significant signs [4]. The result and symptoms of patients in the case series reported in the literature showed consistent with the results and symptoms observed in our study [5,6,8].

The treatment efficacy of ribavirin in CCHF remains unclear. Some studies from our country have reported a decreased mortality rate among the severe cases that were given oral ribavirin treatment, while other studies have reported that ribavirin has no effects on mortality [9,11,12]. Only eleven patients received oral ribavirin and our patients died who treated with oral ribavirin.

Thither is a wide range (2-80%) in the mortality rate in different countries [10]. The average fatality rate for Turkey is around 5% [6]. These rates lower than the reported series from other parts of the world. Unfortunately, the case-fatality rate of our patients was higher than others series reported from other regions of our country (12% vs. 5%).

## 5. CONCLUSION

In conclusion, the CCHF virus causes severe viral hemorrhagic fever outbreaks. CCHF remains a seasonal problem in the Mid-Eastern Anatolia region of Turkey. In the absence of a vaccine, the only way to reduce infection in people is by raising awareness of the risk factors and educating people about the measures they can take to reduce exposure to the virus. Particularly in cases coming from regions categorized as endemic, it is concluded that mortality can be brought down by carefully taken medical history and practice medical treatment and replacement therapies in consideration of CCHF pre-diagnosis.

## CONSENT

All authors declare that 'written informed consent was obtained from the patients for publication of this paper. No conflict interests were declared.

## ETHICAL APPROVAL

It is not applicable.

## COMPETING INTERESTS

Authors have declared that no competing interests exist.

## REFERENCES

1. Naderi H, Sheybani F, Bojdi A, et al. Fatal nosocomial spread of Crimean-Congo hemorrhagic fever with a very short incubation period. *Am J Trop Med Hyg.* 2013;88:469-71.
2. Tezer H, Sayılı RT, Metin A, et al. Lymphocyte subgroups of children with CCHF A marker for prognosis. *J Infect.* 2009;59:291-293.
3. Tezer H, Ayrancı Sucaklı I, Sayılı TR, et al. Crimean-Congo hemorrhagic fever in children. *J Clin Virol.* 2010;48:184-6.

4. Ergönül O. Crimean-Congo hemorrhagic fever. *Lancet Infect Dis.* 2006;6:203-14.
5. Günes T, Engin A, Poyraz O, et al. Crimean-Congo hemorrhagic fever virus in high-risk population, Turkey. *Emerg Infect Dis.* 2009;15:461-4.
6. Yılmaz GR, Buzgan T, Irmak H, et al. The epidemiology of Crimean-Congo hemorrhagic fever in Turkey, 2002-7. *Int J Infect Dis.* 2009;13:380-386.
7. Jamil B, Hasan RS, Sarwari AR, et al. Crimean- Congo hemorrhagic fever: Experience at a tertiary care hospital in Karachi, Pakistan. *Trop Med Hyg.* 2005; 99:577-84
8. Ozkurt Z, Kiki I, Erol S. Crimean-Congo hemorrhagic fever in Eastern Turkey: Clinical features, risk factors and efficacy of ribavirin therapy. *J Infect.* 2006;52:207-215.
9. Ergönül Ö, Çelikbaş A, Dokuzoğuz B et al. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. *Clin Infect Dis.* 2004;39: 284-7.
10. Alavi-Naini R, Moghtaderib A, Koohpayeha HR, et al. Congo/Crimean hemorrhagic fever in Southeast of Iran. *J Infect.* 2006;52:378-82.
11. Watts DM, Ussery MA, Nash D, et al. Inhibition of Crimean-Congo hemorrhagic fever viral infectivity yields *in vitro* by ribavirin. *Am J Trop Med Hyg.* 1989;41: 581-5.
12. Bodur H, Erbay A, Akıncı E, et al. Effects of oral ribavirin treatment on the viral load and disease progression in Crimean-Congo hemorrhagic fever. *Int J Infect Dis.* 2011;15:44-7.

© 2016 Çelik et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Peer-review history:*  
*The peer review history for this paper can be accessed here:*  
<http://sciencedomain.org/review-history/14344>